HTG Molecular Diagnostics Announces $7.5 Million Private Placement

TUCSON, Ariz., March 18, 2022 (GLOBE NEWSWIRE) — HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company whose mission is to advance precision medicine, today announced that it has entered into a definitive securities purchase agreement to sell securities in a private placement with a leading healthcare investor. The gross proceeds to HTG from the private placement, before deducting the placement agent fees and other estimated fees and expenses related to the private placement, are expected to be approximately $7.5 million. HTG intends to use the net proceeds from the private placement for working capital and general corporate purposes.   

Continue reading

Nearly 100 Organizations and Experts Urge HHS Secretary Xavier Becerra to Reject Xtandi March-In Petition

WASHINGTON, D.C. (March 17) — In a letter transmitted today, the Bayh-Dole Coalition and nearly 100 prominent academic and private sector innovation experts and organizations, public policy associations, and legal scholars urged U.S. Department of Health and Human Services Secretary Xavier Becerra to reject the latest march-in petition on prostate cancer drug Xtandi.Continue reading

Help AZBio Tell Arizona’s Bioscience Story

 Arizona has one of the top emerging bioscience and healthcare sectors in the United States.  But, most people have never seen you in action.  AZBio wants to change that! AZBio Communication Campaigns put AZBio Members Companies in the spotlight.  Send us your  photos,  videos, and press releases.Continue reading

OncoMyx Appoints Robert Williamson Chief Business and Chief Financial Officer

PHOENIX–(BUSINESS WIRE)–OncoMyx Therapeutics, a privately-held oncolytic virus immunotherapy company, today announced the appointment of Robert Williamson as Chief Business and Chief Financial Officer. Mr. Williamson has more than two decades of experience in building, financing, and leading private and public biotechnology companies through critical phases of growth. At OncoMyx, Mr. Williamson will lead the business development and financing strategies to maximize the company’s pipeline of multi-armed myxoma immunotherapies for the treatment of solid tumors and hematological malignancies.Continue reading